Biotech cost cuts narrow pipelines as companies prioritize key assets

Ultragenyx plans a 20% workforce reduction, $350 million in 2027 R&D spending and exits from Angelman and Wilson’s disease programs as it pursues profitability. Agios has also announced R&D reductions; the reset raises the importance of remaining pipeline assets, particularly Ultragenyx’s DTX301 Phase 3 results expected next year. Clinical execution and funding for priority programs remain uncertain.